164 related articles for article (PubMed ID: 30006600)
1. Computational delineation and quantitative heterogeneity analysis of lung tumor on 18F-FDG PET for radiation dose-escalation.
Wang X; Cui H; Gong G; Fu Z; Zhou J; Gu J; Yin Y; Feng D
Sci Rep; 2018 Jul; 8(1):10649. PubMed ID: 30006600
[TBL] [Abstract][Full Text] [Related]
2. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
[TBL] [Abstract][Full Text] [Related]
3. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
4. IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
Fleckenstein J; Kremp K; Kremp S; Palm J; Rübe C
Strahlenther Onkol; 2016 Feb; 192(2):75-82. PubMed ID: 26438071
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumour motion compensation and delineation methods on FDG PET-based dose painting plan quality for NSCLC radiation therapy.
Thomas HM; Kinahan PE; Samuel JJE; Bowen SR
J Med Imaging Radiat Oncol; 2018 Feb; 62(1):81-90. PubMed ID: 29193781
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
[TBL] [Abstract][Full Text] [Related]
7. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
[TBL] [Abstract][Full Text] [Related]
8. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients.
Wijsman R; Grootjans W; Troost EG; van der Heijden EH; Visser EP; de Geus-Oei LF; Bussink J
Nucl Med Commun; 2016 Jan; 37(1):66-73. PubMed ID: 26440570
[TBL] [Abstract][Full Text] [Related]
10. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
Even AJ; van der Stoep J; Zegers CM; Reymen B; Troost EG; Lambin P; van Elmpt W
Radiother Oncol; 2015 Aug; 116(2):281-6. PubMed ID: 26238010
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.
Ding XP; Zhang J; Li BS; Li HS; Wang ZT; Yi Y; Sun HF; Wang DQ
Asian Pac J Cancer Prev; 2012; 13(1):319-23. PubMed ID: 22502693
[TBL] [Abstract][Full Text] [Related]
12. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
[TBL] [Abstract][Full Text] [Related]
14. The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk.
Hoffmann L; Knap MM; Khalil AA; Lutz CM; Sloth Møller D
Acta Oncol; 2018 Apr; 57(4):473-479. PubMed ID: 28830293
[TBL] [Abstract][Full Text] [Related]
15. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric implications of the addition of 18 fluorodeoxyglucose-positron emission tomography in CT-based radiotherapy planning for non-small-cell lung cancer.
Vinod SK; Kumar S; Holloway LC; Shafiq J
J Med Imaging Radiat Oncol; 2010 Apr; 54(2):152-60. PubMed ID: 20518880
[TBL] [Abstract][Full Text] [Related]
17. Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?
Peeters ST; Dooms C; Van Baardwijk A; Dingemans AM; Martinussen H; Vansteenkiste J; Decaluwé H; De Leyn P; Yserbyt J; Nackaerts K; De Wever W; Deroose CM; De Ruysscher D
Radiother Oncol; 2016 Aug; 120(2):273-8. PubMed ID: 27291644
[TBL] [Abstract][Full Text] [Related]
18.
Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
[TBL] [Abstract][Full Text] [Related]
20. [What dose escalation in the treatment of locally advanced non-small cell lung cancer?].
Thureau S; Mallet R; Gouel P; Modzelewski R; Vera P
Cancer Radiother; 2022 Oct; 26(6-7):890-893. PubMed ID: 36075830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
